Natera Acquires Foresight Diagnostics
New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting
Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer Symposium
Natera (NASDAQ:NTRA) was given a new $265.00 price target on by analysts at Morgan Stanley.
Natera (NASDAQ:NTRA) had its price target raised by analysts at JPMorgan Chase & Co. from $240.00 to $250.00. They now have an "overweight" rating on the stock.